Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombolytic therapy for acute ischaemic stroke.

Damian Jenkinson1

  • 1Royal Bournemouth and Christchurch Hospitals NHS Trust, Christchurch BH23 2JX.

Hospital Medicine (London, England : 1998)
|April 1, 2004
PubMed
Summary

Recombinant tissue plasminogen activator (rt-PA) is the only licensed treatment for acute ischemic stroke in the UK. Evidence shows rt-PA can improve long-term outcomes for carefully selected stroke patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prepare: Improving End-of-Life Care Practice in Stroke Care: Insights from a National Survey and Semi-Structured Interviews.

Healthcare (Basel, Switzerland)·2025
Same author

European Stroke Organisation certification of stroke units and stroke centres.

European stroke journal·2019
Same author

HeART of Stroke: randomised controlled, parallel-arm, feasibility study of a community-based arts and health intervention plus usual care compared with usual care to increase psychological well-being in people following a stroke.

BMJ open·2019
Same author

The challenges of implementing a telestroke network: a systematic review and case study.

BMC medical informatics and decision making·2013
Same author

Treatment components for upper limb rehabilitation after stroke: a survey of UK national practice.

Disability and rehabilitation·2013
Same author

Developing an education framework for stroke.

Nursing times·2013

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Recombinant tissue plasminogen activator (rt-PA), also known as alteplase, is the sole licensed thrombolytic medication for acute ischemic stroke in the United Kingdom.
  • Its administration is a critical intervention in emergency stroke care.

Purpose of the Study:

  • To review the existing evidence supporting the use of rt-PA in managing acute ischemic stroke.
  • To evaluate the potential of rt-PA to enhance long-term clinical outcomes for specific patient cohorts within a structured stroke service.

Main Methods:

  • Literature review of clinical trials and observational studies on rt-PA in acute stroke.
  • Analysis of data pertaining to patient selection criteria and treatment protocols.
  • Assessment of studies reporting on short-term efficacy and long-term functional recovery.

Main Results:

  • rt-PA demonstrates efficacy in dissolving blood clots responsible for ischemic stroke.
  • Patient selection based on time since symptom onset and stroke severity is crucial for optimal results.
  • Early administration of rt-PA is associated with improved chances of functional recovery.

Conclusions:

  • rt-PA is a vital therapeutic option for selected patients with acute ischemic stroke.
  • Integration of rt-PA treatment within a comprehensive stroke service framework is essential for maximizing patient benefit.
  • Further research may refine patient selection and treatment protocols for even better outcomes.

Related Experiment Videos